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Abstract
Background: The progression of many solid tumors is characterized by the release of tumor-associated proteases
and the detection of tumor specific proteolytic activity in serum specimens is a promising diagnostic tool in
oncology. Here we describe a mass spectrometry-based functional proteomic profiling approach that tracks the
ex-vivo degradation of a synthetic endoprotease substrate in serum specimens of colorectal tumor patients.
Methods: A reporter peptide (RP) with the amino acid sequence WKPYDAAD was synthesized that has a known
cleavage site for the cysteine-endopeptidase cancer procoagulant (EC 3.4.22.26). The RP was added to serum
specimens from colorectal cancer patients (n = 30), inflammatory controls (n = 30) and healthy controls (n = 30) and
incubated under strictly standardized conditions. The proteolytic fragment of the RP was quantified with liquid
chromatography / mass spectrometry (LC/MS).
Results: RP-spiking showed good intra- and inter-day reproducibility with coefficients of variation (CVs) that did not
exceed a value of 10%. The calibration curve for the anchor peptide was linear in the concentration range of
0.4 – 50 μmol/L. The median concentration of the RP-fragment in serum specimens from tumor patients
(TU: 17.6 μmol/L, SD 9.0) was significantly higher when compared to non-malignant inflammatory controls
(IC: 11.1 μmol/L, SD 6.1) and healthy controls (HC: 10.3 μmol/L, SD 3.1). Highest area under receiver operating
characteristic (AUROC) values were seen for discrimination of TU versus HC (0.89) followed by TU versus IC (0.77). IC
and HC could barely be separated indicated by an AUROC value of 0.57. The proteolytic activity towards the RP was
conserved in serum specimens that were kept at room temperature for up to 24 hours prior to the analysis.
Conclusion: The proteolytic cleavage of reporter peptides is a surrogate marker for tumor associated proteolytic
activity in serum specimens of cancer patients. A simple, robust and highly reproducible LC/MS method has been
developed that allows the quantification of proteolytic fragments in serum specimens. The preanalytical impact of
sample handling is minimal as the tumor-associated proteolytic activity towards the reporter peptide is stable for at
least up to 24 h. Taken together, the functional protease profiling shows characteristics that are in line with
routinely performed diagnostic assays. Further work will focus on the identification of additional reporter peptides
for the construction of a multiplex assay to increase diagnostic accuracy of the functional protease profiling.
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Background
Proteases play an important role in different biological
processes including cell differentiation, inflammation
and tissue remodelling, haemostasis, immunity, angio-
genesis, apoptosis and malignant disease [1]. Specifically,
proteases are well known factors to promote local pro-
gression and distant metastasis of colorectal cancer and
many other solid tumors [2,3]. Furthermore, there is in-
creasing evidence that proteases also have key functions
in early stages of tumor development [4]. The tumor-
associated proteases are either secreted directly by the
tumor or originate from surrounding connective tissue
and infiltrating leucocytes as a result of tumor-stroma
interaction [5]. Some tumor-associated proteases like
cathepsins, matrix-metalloproteases, kallikreins and can-
cer procoagulant (CP) are released into the bloodstream
and can be used for diagnostic and prognostic purposes
[6-10]. Tumor-associated protease activity in serum spe-
cimens of cancer patients can be monitored using syn-
thetic substrates that are selectively cleaved by the
protease of interest [6-9]. With the use of appropriate
synthetic reporter-peptides (RPs) for spiking of serum
specimens, the reaction conditions that comprise sub-
strate concentration, incubation time and buffer com-
position can be optimized and standardized accordingly
[11]. Furthermore, the proteolytic fragments accumulate
to the level that they become readily detectable by mass
spectrometry [8]. This approach is similar to established
diagnostic assays measuring the proteolytic activity of
distinct enzymes, e.g., coagulation factors [12].
Recently, we have described a functional protease profil-
ing approach using a reporter peptide that is cleaved by
the tumor associated protease cancer procoagulant (EC
3.4.22.26) [8]. However, the analysis of proteolytic frag-
ments was performed with MALDI-TOF mass spectrom-
etry that is only a semi-quantitative method [13] with
limited inter-day reproducibility [8]. Furthermore, proteo-
lytic fragments had to be extracted from serum specimens
with serial affinity purification that is a rather laborious
method with limited throughput and reproducibility. To
alleviate these restrictions, we have developed a robust
and highly reproducible liquid chromatography-mass
spectrometry (LC-MS) assay for the absolute quantifica-
tion of a targeted proteolytic fragment.
Serum has a high intrinsic proteolytic activity that leads
to continuous processing of proteins and peptides [14].
To protect the reporter peptide from unwanted and un-
specific processing by exopeptidases the cleavage site
WKPYDAAD is flanked by aminohexanoic acid (see
Table 1). When the reporter peptide is cleaved by the
endoprotease cancer procoagulant after the tyrosine (Y)
[15], the resulting free amino-terminus of the intermediate
fragment is rapidly trimmed down by aminopeptidases
[8]. This results in the accumulation of a protease resistant
anchorpeptide (CP-AP) that consists of aminohexanoic
acid and D-aminoacids (see Table 1). The anchorpeptide
was quantified by liquid chromatography / mass spec-
trometry (LC/MS) with good reproducibility that is in line
with routinely performed diagnostic tests.
The sufficient preanalytical stability of biomarkers is a
prerequisite for routine diagnostic use and we could
demonstrate that the tumor-associated proteolytic activ-
ity towards the reporter peptide is preserved for up to
24 h. Furthermore a small proof-of-concept experiment
(n = 90) was performed to demonstrate the diagnostic
power of functional protease profiling with reporter pep-
tide spiking. Systemic inflammation has been recognized
as serious threat for cancer biomarker discovery [16]
and we selected the collective of control individuals ac-
cordingly. The concentrations of proteolytic fragments
were significantly higher in serum specimens from
tumor patients (TU) when compared to serum from in-
flammatory controls (IC) and healthy controls (HC).
This indicates the presence of the tumor-associated pro-
tease cancer procoagulant that is associated with an
increased cleavage of the reporter peptide in serum spe-
cimens of tumor patients.
Here we present a method to monitor controlled, ex-
vivo peptide breakdown in serum samples using LC/MS
with absolute quantification of the respective fragment
that might lead to an activity based approach for bio-
marker discovery and validation.
Results
LC-MS analysis and absolute quantification of the anchor
peptide
The proteolytic cleavage of the reporter peptide (CP-RP)
by the endoprotease cancer procoagulant results in an
accumulation of the anchor peptide (CP-AP). The amino
acid sequence WKPYDAAD of CP-RP is specifically
cleaved after the aminoacid tyrosine (Y) by the endopro-
tease cancer procoagulant prior to further processing by
serum exopeptidases [8,15]. Finally, the protease-
resistant anchor peptide (CP-AP) m/z 515.795 which
consists of the linker and D-amino acids (Table 1) is
Table 1 Peptide sequences of reporter peptide, anchor
peptide and internal standard








CP-AP Ahx-ateeqlkv 515,795 1.030,59
IS Ahx-ateevlkl 508,300 1.015,61
CP-RP: Cancer Procoagulant-Reporter Peptide. CP-AP: Cancer Procoagulant-
Anchor Peptide. IS: Internal Standard. Ahx: amino hexanoic acid. Lower case
letters indicate D-amino acids.
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accumulating and high concentration is a surrogate
marker for increased proteolytic activity of cancer pro-
coagulant. Figure 1 gives a representative example of
the LC/MS results for CP-AP. Figure 1A shows the
extracted ion chromatogram (XIC) of CP-AP and label-
ling of the respective peak area that was used for quan-
tification. Figure 1B shows the corresponding mass
spectrum within the selected mass window ranging
from m/z 250 to m/z 600. Note that only one peak with
the respective isotopic pattern exceeded the signal in-
tensity of 2 × 107 [a.u.]. This m/z 515.795 was expected
to be the doubly charged molecule CP-AP (Table 1) and
the sequence was verified by tandem mass spectrometry
(Additional file 1: Figure S1). The mass spectra of the
internal standard (IS) are of equal quality regarding the
signal to noise ratio (data not shown). A calibration
curve was prepared using pooled serum of healthy con-
trols that was spiked with four different concentrations
of CP-AP ranging from 0.4 to 50 μmol/L. The linearity
of the calibration curve within this concentration range
was good with a coefficient of determination (R2) of
0.992 (Figure 2).
Optimization of incubation time and reproducibility of
RP-spiking
The quantification of the anchor peptide CP-AP is per-
formed as mass-spectrometric endpoint-assay and the
appropriate incubation time has to be determined. As
expected, the concentration of CP-AP is constantly
increasing during prolongation of the incubation time
from 3 h to 6 h and 22 h (Figure 3A). The accumulation
of CP-AP is approximately five times faster in the tumor
serum (QCT), when compared to a healthy control spe-
cimen (QCH) as indicated by the linear regression
graphs with slopes of 0.836 and 0.164 respectively
(Figure 3A). The incubation for 22 h seems to be prefer-
able as reproducibility of measurements is improved
with increasing signal intensity that is associated with
prolonged incubation time [17]. The CVs are inversely
correlated to the signal intensity and range from 6.8% to
3.0% for CP-AP concentrations of 0.33 μmol/L and
18.7 μmol/L respectively (Figure 3B). Consequently, an
incubation period of 22 h was chosen for any further
experiments.
Inhibition of proteolytic reaction with iodoacetamide
The cysteine-endoprotease cancer procoagulant can spe-
cifically be inhibited by iodoacetamide [18] and different
concentrations of protease inhibitor were added to
spiked serum specimens of a tumor patient. As expected,
the concentration of CP-AP is inversely proportional to
the amount of iodoacetamide concentrations of serum
specimens that were spiked with CP-RP. After 22 h of
incubation the amount of CP-AP that accumulated in
the serum specimen was taken as 100%. In the presence
of 5, 25 and 100 mmol/L jodoacetamide, the CP-AP con-
centration was reduced down to 88%, 63% and 25% re-
spectively (Additional file 2: Figure S2).
Figure 1 Exemplary LC/MS results. LC/MS results of the calibration standard with CP-AP concentration of 0.4 μmol/L (A) Extracted ion
chromatogram (XIC) of CP-AP with extracted mass of 515.795 +/−0.005. The peak area of the respective m/z 515.795 is filled in grey and was
used for quantification. (B) ESI mass spectrum of the anchor peptide eluting at 15 +/− 1 min.
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Preanalytical stability of cancer procoagulant activity
Serum specimens from 6 tumor patients were aliquoted
and stored 0, 3, 6 and 24 h at room temperature prior to
freezing at −80°C. After thawing, reporter peptide CP-
RP was added to serum specimens and incubated 22 h
under standardized conditions as described in materials
and methods. The concentrations of CP-AP in the
serum specimens without preanalytical time delay (0 h)
ranged from 4.27 μmol/L to 13.14 μmol/L and were set
to 100%. Compared to freshly prepared specimens (0 h)
the CP-AP concentrations after 3, 6 and 24 h of preana-
lytical time had median values of 103%, 102% and 97%
respectively (Figure 4). The concentrations of CP-AP in
serum specimens with prolonged preanalytical time span
(3 h, 6 h, 24 h) were not significantly different from con-
centrations that were measured in fresh specimens (0 h).
This indicates that cancer procoagulant activity towards
the reporter peptide is stable at least over a preanalytical
time period of 24 h.
Functional protease profiling
Finally, we set up a proof-of-concept experiment to elu-
cidate the applicability of protease profiling for diagnos-
tic purposes. However, the implementation of MS as a
routine diagnostic tool clearly depends on good inter-
day reproducibility of the method. Three aliquots of a
serum specimen from one tumor patient were randomly
integrated into small series of serum specimens from
patients and control individuals on four consecutive
days. The median concentration of CP-AP was
31.9 μmol/L with SD of 3.3 μmol/L and CV of 10.2%
(Additional file 3: Figure S3). As expected, the inter-day
reproducibility is not as good as the intra-day reproduci-
bility (see Figure 3B). However, CVs of 10% or even
Figure 2 Calibration curve of anchor peptide m/z 515,795.
Measurements for each CP-AP concentration (0.4; 4; 20 and
50 μmol/L) were performed in triplicate and linear regression was
calculated with median values. Error bars indicate the standard
deviation. Coefficient of determination (R2) is displayed in the graph.
Figure 3 Kinetic measurements of CP-AP in pooled serum specimens of tumor patients and healthy controls. (A) Accumulation of CP-AP
correlates with incubation time. Linear regression was calculated from median values of five measurements. Squares: pooled serum specimen
from tumor patients. Triangles: pooled serum specimen from healthy controls. The equations of the linear regression and coefficients of
determination (R2) are displayed in the graph. (B) Intraday-reproducibility. Inverse correlation of concentrations of CP-AP and coefficients of
variations (CVs) for five repetitive measurements. The CVs (y-values) are shown next to the squares in the graph. A logarithmic regression has
been calculated with Excel (Microsoft) and the equation and coefficients of determination (R2) are also displayed in the graph.
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more are acceptable for many routine laboratory assays
[19].
Serum specimens from patients with metastatic colo-
rectal tumors (TP = 30), patients without malignant dis-
ease but elevated acute phase protein CRP (IC = 30) and
healthy controls (HC= 30) were spiked with CP-RP and
internal standard (IS). Samples were incubation for 22 h
and sample preparation prior to LC-MS was performed
as described in materials and methods. The median con-
centrations of CP-AP in the collectives of healthy con-
trols (HC), inflammatory controls (IC) and tumor
patients (TP) were 10.3 (SD 3.1), 11.1 (SD 6.1) and 17.6
(SD 9.0) respectively (Figure 5A). The D’Agostino-
Pearson test was used to asses the normal distribution
within the reporter peptide concentrations. For HC and
IC the p-values were higher than 0.05 indicating a nor-
mal distribution. However, for TU the p-value was <0.05
and the hypothesis that the distribution of the observa-
tions in the sample is normal, was rejected. Accordingly,
further data analysis was performed with the non-
parametric Mann–Whitney test. The concentrations of
CP-AP were not significantly different, when HC versus
IC was compared with the Mann–Whitney test
(p = 0.337). In contrast, the comparison of HC versus TP
and IC versus TP showed statistically significant differ-
ences with p values below 0.005 (Figure 5A). The diag-
nostic accuracy for discrimination of healthy controls
and tumor patients was calculated with receiver operat-
ing characteristics (ROC) that had an area under the
curve (AUC) of 0.89. The ROC-AUC for discrimination
of inflammatory controls and tumor patients had a value
of 0.77. The 95% confidence intervals ranged from 0.787
to 0.958 and from 0.646 to 0.871 respectively. In con-
trast, inflammatory controls and healthy controls could
not be differentiated with a ROC-AUC of 0.57 with 95%
confidence interval ranging from 0,438 to 0,699
(Figure 5B). These data suggest that the activity of the
tumor-associated endoprotease cancer procoagulant is
increased in serum specimens of tumor patients when
compared to healthy and inflammatory controls.
Discussion
The dysregulation of protease activity plays an important
role for the initiation and progression of malignant dis-
ease [1,4]. Tumor-associated proteases like matrix metal-
loproteases, cathepsins, kallikrein related peptidases and
members of the plasminogen activator system are
secreted into the bloodstream and might be candidates
for functional protease profiling (for review see [20]).
Specifically, the tumor-associated protease cancer pro-
coagulant is secreted from numerous malignancies in-
cluding colorectal cancer into the bloodstream [21].
Under in vivo conditions this can cause paraneoplastic
coagulopathy throughout cleavage and activation of the
coagulation factor X heavy chain (P00742) [22]. The re-
porter peptide CP-RP comprises the cleavage site
WKPYDAAD that is part of the coagulation factor X
and is preferably cleaved in serum specimens of tumor
patients [8]. Adding reporter peptides to serum speci-
mens enables the monitoring of tumor-related proteo-
lytic activity for diagnostic use [7-9,23,24]. Furthermore,
reporter peptide spiking offers major advantages over
native MS-based peptide profiling concerning the
standardization of preanalytical variabilities [6,11]. The
Figure 4 Preservation of protease activity in a preanalytical time period of 24 h. Aliquots of serum specimens from 6 tumor patients were
frozen at −80°C directly after centrifugation (0 h) or after prolonged preanalytical time span of 3 h, 6 h, and 24 h. After thawing, specimens were
spiked with CP-RP and incubated for 22 h prior to peptide extraction with TCA and LC-MS. CP-AP peak areas were extracted from the data. The
CP-AP concentrations of the freshly obtained serum aliquots (0 h) were set to 100%. In the box plot the central box represents the values from
the lower to upper quartile (25 to 75 percentile). The middle line represents the median. The horizontal line extends from the minimum to the
maximum value. P-values of the Mann–Whitney test are indicated.
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main focus of our present work was to optimize func-
tional protease profiling with respect to simplified sam-
ple preparation and increased inter-day reproducibility
to make it amenable as a laboratory assay for routine
diagnostic use.
Recently, a sample clean-up with trichloroacetic acid
(TCA) has been described that showed a sufficient
recovery for peptides with a molecular weight of less
than 3000 Da [25]. Furthermore, the LC-MS technique
is the method of choice for the reproducible quantifica-
tion of small molecules like peptides in clinical speci-
mens [26], and accordingly this technology was selected
for assay development. Even at low CP-AP concentra-
tions of 0.4 μmol/L the extracted ion chromatogram of
Figure 5 Proof-of-concept experiment for functional protease profiling with reporter peptide spiking. Serum specimens were spiked with
CP-RP and IS and incubated for 22 h as described in materials and methods. (A) CP-AP concentrations in serum specimens of healthy controls
(HC), inflammatory controls (IC) and tumor patients (TP). In the box plot the central box represents the values from the lower to upper quartile
(25 to 75 percentile). The middle line represents the median. The horizontal line extends from the minimum to the maximum value. P-values of
the Mann–Whitney test are indicated. (B) ROC-AUC calculation for separation of tumor patients (TP) from healthy controls (HC) (left graph), tumor
patients (TP) from inflammatory controls (IC) (middle graph) and healthy controls from inflammatory controls (IC) (right graph).
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CP-AP with m/z 515.795 shows only one single peak
(see Figure 1) and this excellent signal to noise ratio
makes quantitative LC/MS analyses amenable [27,28].
Recently, criticism has been raised against functional
protease profiling and it has been suggested to
characterize the proteolytic activity in more detail [29].
Here, we demonstrate that the proteolytic processing of
CP-RP and thus the accumulation of CP-AP can be
inhibited by the addition of a protease inhibitor. Iodoa-
cetamide is a known cysteine protease inhibitor and
reacts readily with the free thiol of cysteine residues
required for the hydrolyzing proteases such as cancer
procoagulant [18,30]. The amount of CP-AP that is gen-
erated in the serum of cancer patients is inversely pro-
portional to the concentration of iodoacetamide added
(Additional file 2: Figure S2). This demonstrates that the
cleavage of CP-RP and the accumulation of CP-AP is a
specific reaction that is related to cysteinprotease
activity.
Most interestingly, the proteolytic activity of serum
specimens towards CP-RP is conserved for up to 24 h
indicating a good preanalytical stability making it useful
for diagnostic application (Figure 4).
One major challenge of functional protease profiling is
the appropriate selection of exogenous reporter peptides,
which are exclusively cleaved by tumor-associated pro-
teases. However, serum is a difficult matrix with high in-
trinsic proteolytic activity caused by different
endoproteases e.g. from the coagulation cascade and the
complement system [14,31,32] as well as a multitude of
exoproteases [33]. Furthermore, the proteolytic profile in
blood specimens is not only altered in malignant disease
but also under non-malignant conditions e.g. inflamma-
tion [16]. In order to be useful for diagnostics, such pro-
teolytic patterns must be distinguishable from e.g. the
inflammatory responses in unrelated non-malignant
conditions. As these patterns overlap to a great extent,
the classification of tumour patients on the basis of pro-
teolytic activity is a demanding task. Our study addresses
this important question by demonstrating the diagnostic
accuracy of functional protease profiling with exogenous
reporter peptides in a proof-of-concept experiment in-
cluding patients with inflammatory conditions during
non-malignant diseases into the control cohort. Most
importantly, there were no statistically significant differ-
ences of CP-AP concentrations between the healthy con-
trols and inflammatory controls, while CP-AP
concentrations were significantly higher in serum speci-
mens from tumor patients (see Figure 5A). This indi-
cates that changes of the proteolytic profile related to
inflammation do not affect the specific processing of the
reporter peptide CP-RP. However, we emphasize that
this small proof-of-principle profiling experiment has
serious shortcomings concerning the limited number of
analyzed specimens and the selection of late-stage tumor
patients with highly elevated CEA concentrations (see
Table 2). Further studies will have to integrate also early
tumor stages and in addition should evaluate the impact
of therapeutic interventions to clarify the potential bene-
fit of functional protease profiling. Finally, it is likely that
tumor heterogeneity during progression of malignant
disease may result in different protease patterns [34].
Based on the use of one single reporter peptide as shown
here this needs to be accommodated to ensure high
diagnostic accuracy and accordingly the areas under the
ROC curves were ‘only’ 0.89 and 0.77 for the discrimin-
ation of tumor patients versus healthy controls and
tumor patients versus inflammatory controls respectively
(see Figure 5B). To increase the diagnostic accuracy of
functional protease profiling, it seems reasonable to
combine different reporter peptides for multiplex ana-
lysis that has potentially superior diagnostic accuracy
[35]. To achieve this goal, it will be necessary to system-
atically identify reporter peptide sequences that are most
efficiently cleaved by disease-specific proteases. However,
any multiplex assay for functional protease profiling
might implement the development of kinetic measure-
ments and the need for chromogenic protease substrates
Table 2 Patient demographics and clinical characteristics
Diagnosis CEA [μg/l] CRP [mg/l] Sex Age
Classification Disease n Mean SD Mean SD Male Female Mean SD
HC not reported 30 3,3 1,3 3,3 2 10 20 50,0 9,4






TU CRC 30 597,6 1014,7 10,9 7 14 16 66,2 10,4
HC; healthy controls. IC; inflammatory controls. TU; tumor patients. UTI; urinary tract infection. IBD; inflammatory bowel disease. Reference range of CEA: <5 μg/l.
Reference range of CRP: <5 mg/l.
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[36]. Further work will focus on the identification of
additional reporter peptides that are cleaved by other
tumor-associated proteases e.g. metalloproteases, cathe-
psins or kallikreins in order to construct a multiplex
protease profiling assay with increased diagnostic sensi-
tivity and specificity.
Conclusion
Here we present an optimized LC/MS assay for the
quantification of a reporter peptide fragment that corre-
lates with tumor-associated proteolytic activity in serum
specimens of colorectal cancer patients. With this
improved method three major observations could be
made: First, the reproducibility of the assay is excellent
with coefficients of variation that did not exceed 10%.
Second, the tumor-associated proteolytic activity to-
wards the reporter peptide is stable in serum specimens
for up to 24 hours. Specifically, good reproducibility and
sufficient preanalytical stability are major prerequisites
of laboratory diagnostic assays. Third, inflammatory con-
trols (IC) could fairly be separated from tumorpatients
(TP) and this is most important as inflammation is an
inherent component of cancer and many studies have
identified biomarkers that are associated with inflamma-
tion rather than malignancy [16]. However, there is a
considerable overlap concerning the concentration of
CP-AP in serum specimens from controls and tumorpa-
tients. The combination of multiple reporter peptides
that are processed by different tumor-associated pro-
teases will be necessary to increase diagnostic accuracy
of functional protease profiling. However, if suitable re-
porter peptides are available, the simultaneous quantifi-
cation of multiple anchorpeptides could easily be
adopted for the presented LC/MS method.
Materials and methods
Materials and chemicals
The reporter peptide (CP-RP), the anchor peptide (CP-
AP) and the internal standard (IS) (Table 1) were synthe-
sized in the functional genome analysis laboratory of the
German Cancer Research Centre (Heidelberg, Germany).
HPLC-grade acetonitrile was purchased from Fisher
Chemicals (Germany). Formic acid was purchased from
Sigma (Germany). Phosphate buffered saline pH 7.4
(PBS) was purchased from PAA Laboratories. Protease
buffer: 200 mol/L TrisHCl, 20 mmol/L CaCl2, pH 7.8.
Iodoacetamide and trichloroacetic acid were purchased
from Sigma and Fluka respectively. All reagents and che-
micals were at least of analytical grade.
Serum samples
Whole blood specimens were acquired from patients
with metastatic colorectal tumors (n = 30) and patients
without malignant disease but elevated acute phase
protein CRP (n = 30) at the University Hospital Mann-
heim. Blood from healthy control individuals (n = 30)
was taken from employees of the University Hospital
Mannheim during routine laboratory testing at the
works doctor’s office. Patient characteristics are sum-
marized in Table 2. Blood collection was performed after
we obtained institutional review board approval and
patients’ written informed consent. After a 30 min clot-
ting time at room temperature the specimens were cen-
trifuged at 20°C for 10 min at 3000 x g. The serum was
aliquoted and stored at −80°C until further use. All
serum specimens were refrigerated within 6 hours after
blood withdrawal. Any handling and processing of
serum specimens from tumor patients and controls was
performed in a strictly randomized and blinded manner.
Measurements of C-reactive protein (CRP) and carci-
noembryonic antigene (CEA) were performed on the Di-
mension VistaTM System (Siemens).
Sample preparation
Serum specimens were diluted in the ratio of 1:3 with
PBS to a final volume of 100 μL. The reporter peptide
(CP-RP) and the internal standard (IS) were dissolved in
protease buffer to a concentration of 100 μmol/L for
CP-RP and 20 μmol/L for the IS. The diluted serum (50
μL) and the mix of RP and IS (50 μL) were incubated at
37°C for 3 h, 6 h or 22 h as depicted in results. The in-
cubation was terminated by adding 100 μL of 10% (v/v)
trichloroacetic acid (TCA) and the resulting mixture was
kept at 4°C for 30 min prior to centrifugation for
15 min. at 4°C and 12.000 rpm in a microcentrifuge
(Eppendorf). The supernatant was again centrifuged for
5 min. at 4°C and 12.000 rpm and 2 μL of the super-
natant were injected onto the HPLC-column.
Liquid chromatography – mass spectrometry (LC-MS)
analysis
LC-MS was performed using a nano HPLC system
(UltiMate3000, Dionex) coupled to a linear ion trap
Fourier Transform Ion Cyclotron Resonance mass spec-
trometer (LTQ-FTICR, Thermo Fisher Scientific) with a
chip interface (TriVersa NanoMate, Advion). Analytical
chromatography of CP-AP and IS (see Table 1) was per-
formed on a 75 μm ID C-18 column (Dionex) with a
flow of 300 nL/min and a gradient from 20-35% of buf-
fer B in 23 min.. The composition of buffer A was water
with 0.1% formic acid and buffer B was 80% acetonitrile
with 0,08% formic acid. Each LC run was preceded by a
blank run ensuring lack of carryover of the material
from the previous run. MS analysis was performed in
positive ion mode, with a mass range of 250–600 m/z.
MS/MS analyses were performed on the reporter pep-
tide fragment CP-AP for sequence confirmation.
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Reproducibility of reporter peptide spiking
To monitor the reproducibility of reporter peptide spik-
ing, two distinct quality control samples were generated
comprising serum specimens from five colorectal tumor
patients (QCT) and five healthy control individuals
(QCH), respectively. Both samples were aliquoted and
stored at −80°C until further use. The QCT and QCH-
samples were spiked with the reporter peptide and in-
ternal standard and incubated for 3 h, 6 h and 22 h at
37°C as described above. The proteolytic processing of
the reporter peptide CP-RP resulted in the accumulation
of CP-AP and the respective peak areas were used for
quantification using LCQuan that is part of the Xcalibur
software package (Thermo Fisher Scientific). Each QC-
specimen was processed 5 times and median, standard
deviation (SD) and coefficient of variation (CV) of the
m/z 515.795 peak was calculated with Microsoft Excel
software.
Statistics
The D’Agostino-Pearson test, Mann–Whitney test and
the receiver operating characteristics (ROC) calculations
were performed with MedCalc (MedCalc Software).
Results for continuous variables were expressed with the
medians and standard deviations. Calculated P values of
less than 0.05 were considered to indicate statistical sig-
nificance. Correlation analyses were performed with
Microsoft Excel 2002 SP-2 using the ‘add trendline’
functionality.
Additional files
Additional file 1: Figure S1: Amino acid sequence confirmation of the
anchor peptide Ahx-ateeqlkv (see Table 1). Print screen of the MS/MS
spectra decoding of m/z 515.795 that was performed with PEAKS
software (Bioinformatics Solutions). The unusual amino acid Ahx cannot
be handled by the software and instead is displayed as Lysine (L) that is
an isomer of Ahx and thus produces a fragment with the same mass.
Additional file 2: Figure S2: Inhibition of protease-activity with
iodoacetamide. The protease inhibitor iodoacetamide together with
CP-RP and IS was added to a serum specimen from one tumor patient
and incubated for 22 h prior to LC-MS analyis. Iodoacetamide
concentrations ranged from 5 to 25 and 100 mmol/L. The CP-AP
concentration of the serum specimen without iodoacetamide was set to
100%. Measurements were performed in triplicate and the squares
indicate median values, error bars indicate standard deviations. The
exponential regression was calculated with Excel (Microsoft) and the
coefficient of determination (R2) is shown in the graph.
Additional file 3: Figure S1: Inter day reproducibility of reporter
peptide spiking. One serum specimen was measured three times on four
different days. CP-AP mean value: 31.9 μmol/L. SD: 3.3. CV: 10.2%. The
central box represents the values from the lower to upper quartile (25 to
75 percentile). The middle line represents the median. The horizontal line
extends from the minimum to the maximum value.
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